Literature DB >> 22094384

Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to antipsychotic treatment in patients with schizophrenia.

Concetta Crisafulli1, Alberto Chiesa, Diana De Ronchi, Changsu Han, Soo-Jung Lee, Moon Ho Park, Ashwin A Patkar, Chi-Un Pae, Alessandro Serretti.   

Abstract

The present study is aimed at exploring whether some single nucleotide polymorphisms (SNPs) within GRIA1, GRIA2 and GRIA4 could be associated with schizophrenia and whether they could predict clinical outcomes in Korean in-patients treated with antipsychotics. One hundred forty five patients with MD, 221 in-patients with schizophrenia and 170 psychiatrically healthy controls were genotyped for 17 SNPs within GRIA1, GRIA2 and GRIA4. Baseline and final clinical measures, including the Positive and Negative Symptoms Scale (PANSS), were recorded. No significant association was found with the diagnosis of schizophrenia. We observed an association between rs3813296 genotype and improvement on PANSS negative scores. Our findings provide no evidence for an association between SNPs within GRIA1, GRIA2 and GRIA4 under investigation and schizophrenia susceptibility, although rs3813296 (GRIA2) could be associated with improvement on PANSS negative scores. However, taking into account the several limitations of our study, further research is needed to draw more definitive conclusions.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22094384     DOI: 10.1016/j.neulet.2011.10.074

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

Review 1.  The developmental stages of synaptic plasticity.

Authors:  Christian Lohmann; Helmut W Kessels
Journal:  J Physiol       Date:  2013-10-21       Impact factor: 5.182

2.  Genetic variants of GRIA1 are associated with susceptibility to schizophrenia in Korean population.

Authors:  Won Sub Kang; Jin Kyung Park; Su Kang Kim; Hae Jeong Park; Sang Min Lee; Ji Young Song; Joo-Ho Chung; Jong Woo Kim
Journal:  Mol Biol Rep       Date:  2012-10-08       Impact factor: 2.316

Review 3.  Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms.

Authors:  Gavin P Reynolds; Olga O McGowan; Caroline F Dalton
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

4.  Transcriptome alterations of mitochondrial and coagulation function in schizophrenia by cortical sequencing analysis.

Authors:  Kuo-Chuan Huang; Ko-Chun Yang; Han Lin; Theresa Tsun-Hui Tsao; Sheng-An Lee
Journal:  BMC Genomics       Date:  2014-12-08       Impact factor: 3.969

Review 5.  Emerging Synaptic Molecules as Candidates in the Etiology of Neurological Disorders.

Authors:  Viviana I Torres; Daniela Vallejo; Nibaldo C Inestrosa
Journal:  Neural Plast       Date:  2017-02-26       Impact factor: 3.599

6.  Evidence of an interaction between FXR1 and GSK3β polymorphisms on levels of Negative Symptoms of Schizophrenia and their response to antipsychotics.

Authors:  Antonio Rampino; Silvia Torretta; Barbara Gelao; Federica Veneziani; Matteo Iacoviello; Aleksandra Marakhovskaya; Rita Masellis; Ileana Andriola; Leonardo Sportelli; Giulio Pergola; Alessandra Minelli; Chiara Magri; Massimo Gennarelli; Antonio Vita; Jean Martin Beaulieu; Alessandro Bertolino; Giuseppe Blasi
Journal:  Eur Psychiatry       Date:  2021-04-19       Impact factor: 5.361

7.  SK3 Channel Overexpression in Mice Causes Hippocampal Shrinkage Associated with Cognitive Impairments.

Authors:  Sabine Martin; Marcio Lazzarini; Christian Dullin; Saju Balakrishnan; Felipe V Gomes; Milena Ninkovic; Ahmed El Hady; Luis A Pardo; Walter Stühmer; Elaine Del-Bel
Journal:  Mol Neurobiol       Date:  2016-01-23       Impact factor: 5.590

8.  Modulation on Glutamic Pathway of Frontal-Striatum-Thalamus by rs11146020 and rs3813296 Gene Polymorphism in First-Episode Negative Schizophrenia.

Authors:  Suping Cai; Yahui Lv; Kexin Huang; Wei Zhang; Qiang Wang; Liyu Huang; Jijun Wang
Journal:  Front Neurosci       Date:  2020-04-21       Impact factor: 4.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.